| Sep 30 |
Bristol Myers gets $6.4B Celgene CVR case dismissed: report
|
| Sep 30 |
Sector Update: Health Care Stocks Advance Late Afternoon
|
| Sep 30 |
US Judge Dismisses $6.4 Billion Suit Against Bristol Myers Over Delay in Drug Approvals
|
| Sep 30 |
Bristol Myers beats $6.4 billion lawsuit over delayed cancer drug
|
| Sep 30 |
Prime Medicine stock rallies 15% on Bristol Myers deal, drug updates
|
| Sep 30 |
Bristol, Prime Medicine in deal to develop T-cell therapies
|
| Sep 30 |
Company News for Sep 30, 2024
|
| Sep 30 |
Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline
|
| Sep 30 |
Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies
|
| Sep 30 |
Prime to narrow gene editing research as it strikes deal with Bristol Myers
|
